From a survey of randomized studies we wanted to elucidate the therapeutic gain and the risk of complications with coronary artery bypass grafting (CABG) and percutaneous transluminal angioplasty (PTCA) in stable angina pectoris. The following main conclusions emerged: Invasive revascularization was associated with increased survival (reduced frequency of cardiac death or myocardial infarction) exclusively in patients with three-vessel disease and/or left main lesion accompanied by a decreased left ventricular function. This group accounted for less than 10% of treated patients. With regard to survival, patients with one- and two-vessel disease were better off with conservative treatment. Relief of angina was achieved for a number of years in the majority of patients. Angina recurred earlier following PTCA than CABG. PTCA is considered less traumatic, but a ten times higher need of additional revascularization seems to eliminate this advantage. The frequency of serious complications (including the higher risk at re-revascularization) was > or = 10% after PTCA and > or = 7% after CABG.

Download full-text PDF

Source

Publication Analysis

Top Keywords

stable angina
8
angina pectoris
8
ptca cabg
8
[thirty years
4
years coronary
4
coronary revascularization
4
revascularization stable
4
angina
4
pectoris randomized
4
randomized controlled
4

Similar Publications

Background: Switching from a conventional to a high-sensitivity cardiac troponin (hs-cTn) assay enables detection of smaller amounts of myocardial damage, but the clinical benefit is unclear. We investigated whether switching to a hs-cTnI assay with a sex-specific 99th centile diagnostic threshold was associated with lower 1-year death or new myocardial infarction (MI) in patients with suspected acute coronary syndrome (ACS).

Methods: This pre-post study included nine tertiary hospitals in Australia.

View Article and Find Full Text PDF

Background: The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with chronic coronary syndrome in the setting of optimal medical therapy remains unknown.

Methods And Results: The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) study is a prospective, multicenter, randomized trial of high-dose (pitavastatin 4 mg/day) or low-dose (pitavastatin 1 mg/day) statin therapy in 12 118 patients with chronic coronary syndrome. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or unstable angina requiring hospitalization (major adverse cardiac and cerebral events [MACCE]).

View Article and Find Full Text PDF

Objective: This systematic review aimed to compare the efficacy of various acupuncture dosages for Chronic Stable Angina (CSA) using randomized controlled trials (RCTs), addressing the unclear relationship between dosage and effectiveness despite acupuncture's potential.

Methods: We searched eight bibliographic databases from inception to October 31, 2024, evaluating RCTs comparing acupuncture to placebo or standard care for CSA patients, focusing on angina attack frequency as the primary outcome. Studies were categorized into high (HDG), moderate (MDG), and low (LDG) dosage groups based on acupuncture characteristics: the number of acupoints, total sessions, frequency per week, and the need for "Deqi".

View Article and Find Full Text PDF

Objectives: The aim of this study was to investigate the expression characteristics and interrelationships of FNDC5 and pyroptosis-associated molecules in peripheral blood mononuclear cells of patients with coronary heart disease (CHD).

Methods: Patients were divided into stable angina (SA), unstable angina (UA), and acute myocardial infarction (AMI) groups based on different clinical symptoms. According to the Gensini score, they were then divided into mild, moderate, and severe lesion groups.

View Article and Find Full Text PDF

Peak Procedural ACT Is Associated With All-Cause Mortality After Femoral Access PCI.

J Soc Cardiovasc Angiogr Interv

December 2024

Division of Cardiovascular Medicine, Sulpizio Cardiovascular Center, University of California San Diego, San Diego, California.

Background: A minimum threshold activated clotting time (ACT) to guide heparin dosing during percutaneous coronary intervention (PCI) is associated with lower ischemic complications. However, data are variable regarding the risk of high ACT levels. The aim of this study was to assess the impact of peak procedural ACT on complications and mortality for transfemoral and transradial access PCI.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!